You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 29, 2024

NEUPOGEN Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for NEUPOGEN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Gilead SciencesPhase 2
MedSIRPhase 2
Baylor Research InstitutePhase 2

See all NEUPOGEN clinical trials

Recent Litigation for NEUPOGEN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.2023-01-19

See all NEUPOGEN litigation

PTAB Litigation
PetitionerDate
2016-09-15
2012-09-25

See all NEUPOGEN litigation

Pharmacology for NEUPOGEN
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NEUPOGEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NEUPOGEN Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 ⤷  Try a Trial 2006-03-07 Company disclosures
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 ⤷  Try a Trial 2005-08-23 Company disclosures
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 ⤷  Try a Trial 2013-12-03 Company disclosures
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 ⤷  Try a Trial 2013-12-10 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for NEUPOGEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for NEUPOGEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CR 2014 00004 Denmark ⤷  Try a Trial PRODUCT NAME: LIPEGFILGRASTIM; REG. NO/DATE: EU/1/13/856 20130729
CR 2014 00003 Denmark ⤷  Try a Trial PRODUCT NAME: LIPEGFILGRASTIM; REG. NO/DATE: EU/1/13/856 20130729
SPC/GB14/009 United Kingdom ⤷  Try a Trial PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729
2014/006 Ireland ⤷  Try a Trial PRODUCT NAME: LONQUEX-LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725
14C0007 France ⤷  Try a Trial PRODUCT NAME: LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725
1490007-0 Sweden ⤷  Try a Trial PRODUCT NAME: LIPEFILGRASTIM; REG. NO/DATE: EU/1/13/856 20130725
2002C/040 Belgium ⤷  Try a Trial PRODUCT NAME: PEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/02/227/001 20020823
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.